We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
TECARTUS (Gilead Sciences Pty Ltd)
Product name
TECARTUS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
172 (255 working days)
Active ingredients
T Cells - Brexucabtagene autoleucel, cryopreserved - T - Tecartus
Registration type
Biologicals
Indication
Class 4 biological
TECARTUS is a genetically modified autologous immunocellular therapy for the treatment of patients greater than or equal to 18 years of age with relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (B-ALL).